Marshall Wace, LLP Edgewise Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 29,893 shares of EWTX stock, worth $758,983. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,893
Previous 577,565
94.82%
Holding current value
$758,983
Previous $15.4 Million
94.82%
% of portfolio
0.0%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding EWTX
# of Institutions
214Shares Held
99.8MCall Options Held
885KPut Options Held
240K-
Orbimed Advisors LLC San Diego, CA15MShares$381 Million10.86% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$226 Million3.85% of portfolio
-
Baker Bros. Advisors LP New York, NY6.16MShares$156 Million1.82% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$153 Million0.0% of portfolio
-
Novo Holdings Hellerup, G75MShares$127 Million10.85% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.6B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...